These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15295790)

  • 1. Pharmaceutical impurity identification: a case study using a multidisciplinary approach.
    Alsante KM; Boutros P; Couturier MA; Friedmann RC; Harwood JW; Horan GJ; Jensen AJ; Liu Q; Lohr LL; Morris R; Raggon JW; Reid GL; Santafianos DP; Sharp TR; Tucker JL; Wilcox GE
    J Pharm Sci; 2004 Sep; 93(9):2296-309. PubMed ID: 15295790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of LC-MS(n) in conjunction with mechanism-based stress studies in the elucidation of drug impurity structure: rapid identification of a process impurity in betamethasone 17-valerate drug substance.
    Li M; Lin M; Rustum A
    J Pharm Biomed Anal; 2008 Dec; 48(5):1451-6. PubMed ID: 18977106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification, isolation, characterization and response factor determination of process-related impurity in meprobamate drug substance.
    Karthikeyan K; Arularasu GT; Murali V; Pillai KC
    J Pharm Biomed Anal; 2011 Jan; 54(1):208-12. PubMed ID: 20727702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
    Thomas S; Mathela CS; Agarwal A; Paul SK
    J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
    Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
    J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients.
    Zech SG; Carr M; Mohemmad QK; Narasimhan NI; Murray C; Rozamus LW; Dalgarno DC
    J Antibiot (Tokyo); 2011 Sep; 64(9):649-54. PubMed ID: 21792211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical impurities and degradation products: uses and applications of NMR techniques.
    Maggio RM; Calvo NL; Vignaduzzo SE; Kaufman TS
    J Pharm Biomed Anal; 2014 Dec; 101():102-22. PubMed ID: 24853620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impurity Profile of Bronchodilators used in Asthma: A Critical Review.
    Prajapati KJ; Kothari CS
    Curr Drug Discov Technol; 2018; 15(4):272-304. PubMed ID: 28875855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
    Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product.
    Mohan A; Hariharan M; Vikraman E; Subbaiah G; Venkataraman BR; Saravanan D
    J Pharm Biomed Anal; 2008 May; 47(1):183-9. PubMed ID: 18313249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
    Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
    J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification, isolation and characterization of potential process-related impurity and its degradation product in vildagliptin.
    Kumar N; Devineni SR; Singh G; Kadirappa A; Dubey SK; Kumar P
    J Pharm Biomed Anal; 2016 Feb; 119():114-21. PubMed ID: 26678178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of degradation products of moxidectin using LC, LTQ FT-MS, H/D exchange and NMR.
    Awasthi A; Razzak M; Al-Kassas R; Greenwood DR; Harvey J; Garg S
    Anal Bioanal Chem; 2012 Nov; 404(8):2203-22. PubMed ID: 22986987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR.
    Raman B; Sharma BA; Mahale G; Singh D; Kumar A
    J Pharm Biomed Anal; 2011 Sep; 56(2):256-63. PubMed ID: 21664089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of pharmaceutical impurities in formulated dosage forms.
    Pan C; Liu F; Motto M
    J Pharm Sci; 2011 Apr; 100(4):1228-59. PubMed ID: 24081463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR.
    Raman B; Sharma BA; Butala R; Ghugare PD; Kumar A
    J Pharm Biomed Anal; 2010 May; 52(1):73-8. PubMed ID: 20079995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis and evaluation of the impurity of felodipine and its tablets].
    Zhang N; Yu LJ; Li J; Tong JW; Meng J; Zhang QM; Shi YQ
    Yao Xue Xue Bao; 2012 Feb; 47(2):223-8. PubMed ID: 22512035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural identification and characterization of impurities in ceftizoxime sodium.
    Bharathi Ch; Prasad ChS; Bharathi DV; Shankar R; Rao VJ; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 Jan; 43(2):733-40. PubMed ID: 16950586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impurity profile tracking for active pharmaceutical ingredients: case reports.
    Zhou L; Mao B; Reamer R; Novak T; Ge Z
    J Pharm Biomed Anal; 2007 Jun; 44(2):421-9. PubMed ID: 17142001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.